[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013011259A2 - condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3 - Google Patents

condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3

Info

Publication number
BR112013011259A2
BR112013011259A2 BR112013011259A BR112013011259A BR112013011259A2 BR 112013011259 A2 BR112013011259 A2 BR 112013011259A2 BR 112013011259 A BR112013011259 A BR 112013011259A BR 112013011259 A BR112013011259 A BR 112013011259A BR 112013011259 A2 BR112013011259 A2 BR 112013011259A2
Authority
BR
Brazil
Prior art keywords
hydroxyvitamin
conditions associated
treatment conditions
eotaxin level
increased
Prior art date
Application number
BR112013011259A
Other languages
English (en)
Other versions
BR112013011259B1 (pt
Inventor
Elisabeth Stoecklin
Joseph Schwager
Stephanie Krammer-Lukas
Swen Wolfram
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of BR112013011259A2 publication Critical patent/BR112013011259A2/pt
Publication of BR112013011259B1 publication Critical patent/BR112013011259B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3. a presente invenção relaciona-se com as condições de tratamento/prevenção associadas com um aumento do nível de eotaxina em um ser humano com 25-hidroxivitamina d3 (calcifediol). opcionalmente, a vitamina d3 pode ser usada em conjunto com a 25-hidroxivitamina d3.
BR112013011259A 2010-12-06 2011-12-05 Uso de 25-hidroxivitamina D3 para a fabricação de um produto farmacêutico, alimento, ou nutracêutico para manter níveis saudáveis de eotaxina BR112013011259B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10193847 2010-12-06
PCT/EP2011/071684 WO2012076429A1 (en) 2010-12-06 2011-12-05 Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3

Publications (2)

Publication Number Publication Date
BR112013011259A2 true BR112013011259A2 (pt) 2016-11-01
BR112013011259B1 BR112013011259B1 (pt) 2020-03-03

Family

ID=43585621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011259A BR112013011259B1 (pt) 2010-12-06 2011-12-05 Uso de 25-hidroxivitamina D3 para a fabricação de um produto farmacêutico, alimento, ou nutracêutico para manter níveis saudáveis de eotaxina

Country Status (10)

Country Link
US (2) US20130252927A1 (pt)
EP (1) EP2648737B1 (pt)
JP (1) JP5982695B2 (pt)
KR (1) KR101895764B1 (pt)
CN (2) CN106924268A (pt)
BR (1) BR112013011259B1 (pt)
ES (1) ES2712740T3 (pt)
PL (1) PL2648737T3 (pt)
TR (1) TR201902517T4 (pt)
WO (1) WO2012076429A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
JP5563296B2 (ja) 2006-06-21 2014-07-30 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 二次性副甲状腺機能亢進症の治療及び予防方法
ES2401205T3 (es) 2007-04-25 2013-04-17 Cytochroma Inc. Composiciones de orales de liberación controlada que comprende un compuesto de vitamina D y un soporte céreo
EP3225243A1 (en) 2007-04-25 2017-10-04 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3436026A1 (en) 2016-03-28 2019-02-06 OPKO Ireland Global Holdings, Ltd. Methods of vitamin d treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216178A (ja) * 1982-06-11 1983-12-15 Chugai Pharmaceut Co Ltd ５，６−エポキシ化ビタミンｄ↓３誘導体
CA2005227A1 (en) * 1988-12-14 1990-06-14 Choju Aoki Pharmaceutical preparation for chronic hepatitis treatment
US5043170A (en) 1989-02-14 1991-08-27 Hoffmann-La Roche Inc. Animal feed composition containing a vitamin D metabolite
US5695794A (en) 1995-08-10 1997-12-09 Amoco Corporation Use of 25-hydroxycholecalciferol in a dietary supplement process for ameliorating the effects of tibial dyschondroplasia in poultry while maintaining weight gain
JPH1087495A (ja) * 1996-09-17 1998-04-07 Teijin Ltd 活性型ビタミンｄ含有予防剤あるいは治療剤
AU4919597A (en) * 1996-10-31 1998-05-22 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
JP2000191537A (ja) 1998-12-24 2000-07-11 Teijin Ltd 炎症性呼吸器疾患治療剤
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
PL1516540T3 (pl) 2003-09-22 2013-02-28 Dsm Ip Assets Bv Zastosowanie związków z grupy witaminy D
DE602006016005D1 (de) 2005-11-25 2010-09-16 Dsm Ip Assets Bv Verwendung von 25-hydroxy-vitamin d3 zur verbesserung der vitalität von tieren
US20080038410A1 (en) 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US11752158B2 (en) * 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
EP3225243A1 (en) * 2007-04-25 2017-10-04 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US20110052707A1 (en) * 2008-02-12 2011-03-03 Neil Robert Buck Combination of vitamin d and 25-hydroxyvitamin d 3
BRPI0907952B1 (pt) * 2008-02-13 2023-12-05 Dsm Ip Assets B.V. Composição farmacêutica compreendendo vitamina d e 25- hidroxivitamina d3, nutracêutico, suplemento alimentício ou alimento apropriado e kit para aumento dos níveis de 25- hidroxivitamina d3 no plasma em um humano

Also Published As

Publication number Publication date
BR112013011259B1 (pt) 2020-03-03
EP2648737A1 (en) 2013-10-16
ES2712740T3 (es) 2019-05-14
PL2648737T3 (pl) 2019-05-31
CN103237552A (zh) 2013-08-07
TR201902517T4 (tr) 2019-03-21
WO2012076429A1 (en) 2012-06-14
KR20130135868A (ko) 2013-12-11
CN106924268A (zh) 2017-07-07
CN103237552B (zh) 2018-03-06
JP2013545766A (ja) 2013-12-26
US20170106005A1 (en) 2017-04-20
US20130252927A1 (en) 2013-09-26
US10357501B2 (en) 2019-07-23
EP2648737B1 (en) 2018-11-21
KR101895764B1 (ko) 2018-09-07
JP5982695B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
IN2014DN09782A (pt)
BR112017012434A2 (pt) composições de canabinóide microencapsuladas
IN2012DN06714A (pt)
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
TW201711676A (en) Ferric citrate dosage forms
BRMU8901002Y8 (pt) disposição construtiva para uma bandagem portadora de um dispositivo estimulador de nervos transcutâneo elétrico
MX2011007930A (es) Conjugados de insulina cristalina.
SG10201806787VA (en) Modulators of complement factor b
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
MX2013004598A (es) Rasagilina enriquesida con deuterio.
IN2015DN03069A (pt)
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance
MX2010008280A (es) Composicion para estimular la actividad de celula asesina natural.
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
EP3915565A3 (en) Xanthine oxidase inhibitor formulations
MY175703A (en) Tablets with improved acceptance and good storage stability
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
IN2014KN01772A (pt)
UA44395U (ru) Применение тиоцетама в качестве диуретического средства с мягким мочегонным действием в комплексном лечении

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2011, OBSERVADAS AS CONDICOES LEGAIS

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 16.1 NA RPI NO 2540 DE 10/09/2019 POR TER SIDO INDEVIDA.

B09X Decision of grant: republication
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2011, OBSERVADAS AS CONDICOES LEGAIS.